Privacy Policy
Signals Blog

Contributors

Categories

David Kent

Dr. David Kent is a Principal Investigator at the York Biomedical Research Institute (https://www.york.ac.uk/biology/research/infection-immunity/david-kent/). His laboratory's research focuses on the fundamental biology of blood stem cells and how changes in their regulation lead to cancers. David has a long history of public engagement and outreach including the creation of The Black Hole (https://www.universityaffairs.ca/opinion/the-black-hole/) in 2009. He has been writing for Signals since 2010.

Posts by: David


Is the academy worse than the fashion industry for “following the leader”?

Author: David Kent, 08/27/14

This post originally appeared on The Black Hole blog and is reprinted with permission from the author and University Affairs. I hate to admit this, but I find an incredible number of scientific papers really boring. It seems that more and more, research papers are using the same sets of sexy and expensive tools without actually […]

Careful with the heart strings: Promise vs. potential

Author: David Kent, 06/26/14

> The cellular therapy plenary at the ISSCR conference on June 19 was an incredibly interesting mix of hope and despair. On one hand, the opening talk by Leigh Turner made us imagine thousands of people in the United States getting duped into stem cell therapies as a result of pre-mature commercialization and ethically contentious […]

Location, location, location… Studying stem cells in their homes

Author: David Kent, 06/19/14

> Just four hours after landing in Vancouver for the 2014 meeting of the International Society for Stem Cell Research, I was delighted to attend the late afternoon plenary session on Cell Heterogeneity. Both John Dick and Connie Eaves – juggernauts of the Canadian stem cell community – reminded us of the differences between stem and […]

Will bone marrow stem cells help heart attack patients? Even cowboy trials have a role to play…

Author: David Kent, 05/06/14

> My last post introduced the large-scale publicly funded clinical trial called BAMI (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on all course mortality in Acute Myocardial Infarction). That post focused on the role of the public purse in funding such trials and concluded that public monies have a major role to […]

Testing stem cells in the clinic – a role for publicly funded trials?

Author: David Kent, 04/15/14

> In February this year, the biggest stem cell trial for heart attack patients was begun and will involve over 3000 patients from 11 different countries in Europe. The BAMI trial (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on all course mortality in Acute Myocardial Infarction) aims to demonstrate whether or not […]